Vimarsana
Biggest News Aggregation in the World

Page 44 - Zai Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zai Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zai Lab Today - Breaking & Trending Today

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone - Vimarsana News

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

Seagen Inc. and Genmab A/S announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who...

Head-To-Head Review: Regeneron Pharmaceuticals (NASDAQ:REGN) & Capricor Therapeutics (NASDAQ:CAPR) - Vimarsana News

Head-To-Head Review: Regeneron Pharmaceuticals (NASDAQ:REGN) & Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation. Earnings and Valuation This table compares Capricor Therapeutics […]

Repotrectinib Gets Breakthrough Therapy Designation in China for NTRK+ TKI-Pretreated Solid Tumors - Vimarsana News

Repotrectinib Gets Breakthrough Therapy Designation in China for NTRK+ TKI-Pretreated Solid Tumors

The Center for Drug Evaluation, of the National Medical Products Administration in China, has granted breakthrough therapy designation to repotrectinib for use in patients with advanced solid tumors harboring a NTRK gene fusion who experienced disease progression after TKI treatment.

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China - Vimarsana News

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Zai Lab Limited announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough Therapy Designation for investigational repotrectinib for the...

Zai Lab Shares Up 11% as Repotrectinib Gets Breakthrough Therapy Designation in China - Vimarsana News

Zai Lab Shares Up 11% as Repotrectinib Gets Breakthrough Therapy Designation in China

By Sabela Ojea Shares of Zai Lab on Wednesday climbed after the biotechnology company said the Center for Drug Evaluation of China's National Medical...